Today: 19 May 2026
Browse Category

Healthcare News 13 December 2025 - 30 April 2026

Cigna’s Obamacare Exit Puts 369,000 Members on the Clock for 2027 Coverage

Cigna’s Obamacare Exit Puts 369,000 Members on the Clock for 2027 Coverage

Cigna Group will exit the Affordable Care Act individual insurance market after 2026, affecting about 369,000 members in 11 states who must find new coverage for 2027. The announcement came as Cigna reported first-quarter revenue of $68.5 billion and raised its 2026 earnings outlook. CVS Health’s Aetna previously withdrew from the ACA market for 2026, impacting about 1 million enrollees.
30 April 2026
··
Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche said its experimental MS drug fenebrutinib met the main goal in a late-stage study for primary progressive multiple sclerosis, showing “non-inferiority” to Ocrevus but with more frequent, reversible liver enzyme elevations and a higher share of fatal cases. Roche shares last closed down 0.6% at 356.40 francs. Investors await Monday’s webcast for more data and filing plans.
8 February 2026
····
Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer shares rose 2.7% to $27.22 Friday after the FDA granted Priority Review to its hemophilia drug HYMPAVZI, with a decision expected by mid-2026. Trading volume reached 30 million shares. The company also launched the TrumpRx discount program, offering cash discounts on over 30 drugs. The White House said TrumpRx.gov debuted Thursday with “most-favored nation” pricing on 40 branded drugs.
6 February 2026
···
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
······
Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly shares fell 2.4% to $1,015.05 Wednesday after the company announced a gene-editing deal with Seamless Therapeutics worth up to $1.12 billion. The U.S. government included Lilly’s Trulicity in the next round of Medicare drug-price negotiations, raising pricing concerns. Obesity drug rivals increased ad spending, intensifying competition.
28 January 2026
···
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson shares rose 1.3% Tuesday after the FDA approved a Darzalex Faspro combination for newly diagnosed multiple myeloma patients ineligible for stem-cell transplants. The S&P 500 closed at a record high, while healthcare stocks broadly fell after a Medicare payment proposal. The U.S. also named 15 drugs for future Medicare price negotiations, increasing pressure on big pharma.
28 January 2026
···
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK shares closed down 0.2% at 1,801 pence in London Friday after China approved Trelegy Ellipta for uncontrolled asthma in adults. The expanded label gives GSK access to an estimated 46 million adults with asthma in China. Investors await GSK’s Q4 and full-year results, set for Feb. 4. The FTSE 100 slipped 0.07% on the day.
24 January 2026
·····
ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

ImmunityBio shares surged 39.8% Friday after reporting a 750% jump in 2025 ANKTIVA sales and new regulatory approvals, including in Saudi Arabia. The company said its pivotal bladder cancer trial is over 85% enrolled, with completion targeted for Q2 2026. ImmunityBio ended the quarter with $242.8 million in cash. Investors await audited 2025 results and further updates on ANKTIVA and CAR-NK programs.
17 January 2026
···
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics shares fell 11% to $17.46 Monday after announcing a U.S. FDA biologics license application for its lung cancer drug ivonescimab. The company also disclosed a clinical trial collaboration with GSK to test a combination regimen in solid tumors. Investors are watching for the FDA’s next procedural step and updates from the J.P. Morgan Healthcare Conference.
12 January 2026
·
Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk’s U.S. shares rose 1.4% in premarket trading after the company denied any relationship with SaveRxCanada.to, which claims to sell India-sourced Ozempic to U.S. patients at $280 per pen. Novo said it has not supplied Ozempic to the platform. The dispute comes as drug pricing faces renewed political scrutiny and ahead of the J.P. Morgan Healthcare Conference.
9 January 2026
···
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharmaceuticals shares rose about 18% in premarket trading after the FDA approved its motion-sickness drug Nereus (tradipitant). The company plans to launch the oral treatment in the coming months. The approval followed late-stage trials involving 681 patients. Shares closed at $7.03 Tuesday and were indicated around $8.30 early Wednesday.
31 December 2025
···
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences shares surged on heavy volume to $2.64 after the company presented updated Phase 2 data for SLS009 in relapsed/refractory AML at ASH 2025. The study showed a 46% overall response rate among 35 patients, with no dose-limiting toxicities reported. Final analysis of the Phase 3 REGAL trial for galinpepimut-S is expected by year-end.
23 December 2025
·
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna shares rose about 9% to $33.80 after the company secured up to $54.3 million from CEPI for a Phase 3 trial of its H5 bird flu vaccine. The funding follows a canceled U.S. government contract earlier this year. Meanwhile, U.S. regulators are reviewing possible COVID-19 vaccine safety issues, with conflicting reports on potential FDA warnings.
20 December 2025
·
Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly shares closed at $1,027.51 Friday, up about 3% for the week after late-stage trial data showed its obesity drug retatrutide delivered nearly 29% average weight loss in patients with knee osteoarthritis. The stock rebounded from an early-week dip, outperforming the broader market as investors weighed drug tolerability and future pricing strategy.
13 December 2025
···
1 2

Stock Market Today

  • Euronext Reports 5.8% Rise in FX Trading Revenue in Q1 2026
    May 19, 2026, 12:33 PM EDT. Euronext, a European capital market infrastructure operator, reported a 5.8% year-on-year increase in foreign exchange (FX) trading revenue for the first quarter of 2026. The growth highlights steady demand in FX markets despite volatile economic conditions. Euronext published its quarterly results showing resilience in trading operations, underlying its role in the European financial ecosystem.

Latest articles

Why Constellation Software Stock Is Jumping While Canada’s Market Slips

Why Constellation Software Stock Is Jumping While Canada’s Market Slips

19 May 2026
Toronto, May 19, 2026, 12:05 (EDT) Constellation Software shares jumped on Tuesday, rising 9.5% to C$2,860.21 at 11:40 a.m. in Toronto, as investors bought back into one of Canada’s biggest software names while the broader S&P/TSX composite edged lower. Google Finance showed the stock opening at C$2,625.00 and touching C$2,880.35 intraday. (Google) The move matters because trading resumed after Monday’s Victoria Day closure, giving investors a fresh chance to react to last week’s earnings, analyst calls and the broader debate over whether artificial intelligence will weaken or help the company’s portfolio of niche software businesses. TMX said Canadian exchanges would
InMed Soars 100% on $290M Migraine Deal

InMed Soars 100% on $290M Migraine Deal

19 May 2026
InMed Pharmaceuticals shares jumped 108.6% to $1.42 after agreeing to merge with Mentari Therapeutics in an all-stock deal, shifting focus to migraine prevention. The combined company will operate as Mentari, backed by a $290 million private placement, with InMed shareholders owning about 1.51%. Nearly 69.6 million shares traded, and InMed’s market value reached $5.7 million.
Anthropic Brings on OpenAI Co-Founder Andrej Karpathy

Anthropic Brings on OpenAI Co-Founder Andrej Karpathy

19 May 2026
Anthropic has hired Andrej Karpathy, a founding OpenAI member and former Tesla AI executive, to join its pre-training team. Karpathy will work under Nick Joseph and lead efforts to use Claude to speed pre-training research. He starts this week. Anthropic has also added Chris Rohlf, a cybersecurity specialist, to its frontier red team.

Popular

Go toTop